Protein Posttranslational Modification: A Potential Target in Pharmaceutical Development

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 417-441

  Mostaqul Huq, M D ^a   Wei, Li Na ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Prokaryotic versus eukaryotic PTM; Protein posttranslational modification (PTM); PTM role in cellular function and cell signaling

Indexed keywords

EID: 84889863223     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch4d     Document Type: Chapter

References (59)

1. Gooley A A, Packer N H (1997). The importance of protein co- and post-translational modifications in proteome projects. In M.R. Wilkins; K.L. Williams; R.D. Appel; et al. (eds.), Springer-Verlag, Proteome Research: New Frontiers in Functional Genomics: Berlin. pp. 65-91.
2. Pandey A, Mann M (2000). Proteomics to study genes and genomes. Nature. 405: 837-846.
3. Liebler D C (2001). Introduction to Proteomics: Tools for the New Biology. Humana Press, Totowa, NJ.
4. Huq M D, Khan S A, Park S W, et al. (2005). Mapping of phosphorylation sites of nuclear corepressor receptor interacting protein 140 by liquid chromatography-tandem mass spectrometry. Proteomics. 5:2157-2166.
5. Huq M D, Wei L N (2005). Post-translational modification of nuclear corepressor receptor- interacting protein 140 by acetylation. Mol. Cell. Proteomics. 4:975-983.
6. Barlev N A, Liu L, Chehab N H, et al. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 8:1243-1254.
7. Bedford M T, Richard S (2005). Arginine methylation an emerging regulator of protein function. Mol. Cell. 18:263-272.
8. Wells L, Vosseller K, Hart G W (2001). Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 291:2376-2378.
9. Stadman E R (2001). Protein oxidation in aging and age-related diseases. Ann. N.Y. Acad. Sci. 928:22-38.
10. Johnson E S (2004). Protein modification by SUMO. Ann. Rev. Biochem. 73:355-382.
11. Lee D Y, Teyssier C, Strahl B D, et al. (2005). Role of protein methylation in regulation of transcription. Endocr. Rev. 26:147-170.
12. Park S W, Huq M D, Hu, X, et al. (2005). Tyrosine nitration on p65: A novel mechanism to rapidly inactivate nuclear factor-kappaB. Mol. Cell. Proteomics. 4:300-309.
13. Teyssier C, Ma, H, Emter R, et al. (2005). Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. Genes Dev. 19:1466-1473.
14. Rochette-Egly C (2003). Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell. Signal. 15:355-366.
15. Cote J, Boisvert F M, Boulanger M C, et al. (2003). Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol. Biol. Cell. 14:274-287.
16. Cheng X, Hart G W (2001). Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta: post-translational regulation of turnover and transactivation activity. J. Biol. Chem. 276:10570-10575.
17. McCann J P, Mayes J S, Hendricks G R, et al. (2001). Subcellular distribution and glycosylation pattern of androgen receptor from sheep omental adipose tissue. J. Endocrinol. 169:587-593.
18. Khan S A, Park S W, Huq M, et al. (2005). Protein kinase C-mediated phosphorylation of orphan nuclear receptor TR2: effects on receptor stability and activity. Proteomics. 5:3885-3894.
19. Gronemeyer H, Gustafsson J A, Laudet V (2004). Principles for modulation of the nuclear receptor superfamily. Nature Rev. Drug Disc. 3:950-964.
20. Goody R S, Durek T, Waldmann H, et al. (2005). Application of protein semisynthesis for the construction of functionalized posttranslationally modified rab GTPases. Methods Enzymol. 403:29-42.
21. Acconcia F, Ascenzi P, Bocedi A, et al. (2004). Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol. Biol. Cell. 16:231-237.
22. Xu W, Cho H, Evans R M (2003). Acetylation and methylation in nuclear receptor gene activation. Methods Enzymol. 364:205-223.
23. Fu M, Wang C, Zhang X, et al. (2004). Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem. Pharmacol. 68:1199-1208.
24. Chen L F, Williams S A, Mu, Y, et al. (2005). NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25:7966-7975.
25. Chuikov S, Kurash J K, Wilson J R, et al. (2004). Regulation of p53 activity through lysine methylation. Nature. 432:353-360.
26. Chevillard-Briet M, Trouche D, Vandel L (2002). Control of CBP co-activating activity by arginine methylation. EMBO.J. 21:5457-5466.
27. Rezai-Zadeh N, Zhang X, Namour F, et al. (2003). Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev. 17:1019-1029.
28. Chan W M, Mak M C, Fung T K, et al. (2006). Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol. Cancer Res. 4:15-25.
29. Wurgler-Murphy S M, King D M, Kennelly P J (2004). The Phosphorylation Site Database: A guide to the serine-, threonine-, and/or tyrosine-phosphorylated proteins in prokaryotic organisms. Proteomics. 4:1562-1570.
30. Goy M F, Springer M S, Adler J (1977). Sensory transduction in Escherichia coli: role of a protein methylation reaction in sensory adaptation. Proc. Nat. Acad. Sci. USA. 74:4964-4968.
31. Eichler J, Adams M W (2005). Posttranslational protein modification in Archaea. Microbiol. Mol. Biol. Rev. 69:393-425.
32. Wu R C, Qin J, Yi P, et al. (2004). Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell. 15:937-949.
33. Vo N, Fjeld C, Goodman R H (2001). Acetylation of nuclear hormone receptorinteracting protein RIP140 regulates binding of the transcriptional corepressor CtBP. Mol. Cell. Biol. 21:6181-6188.
34. Gupta P, Huq M D, Khan S A, et al. (2005). Regulation of co-repressive activity of and HDAC recruitment to RIP140 by site-specific phosphorylation. Mol. Cell. Proteomics. 4:1776-1784.
35. Zhang K, Yau, P M, Chandrashekhar B, et al. (2004). Differentiation between peptides containing acetylated or tri-methylated lysines by mass spectrometry: An application for determining lysine 9 acetylation and methylation of histone H3. Proteomics. 4:1-10.
36. Hirota J, Satomi Y, Yoshikawa K, et al. (2003). ε-N,N,N-trimethyllysine-specific ions in matrix-assisted laser desorption/ionization-tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17:371-376.
37. Johnstone R W (2004). Deamidation of Bcl-X(L): a new twist in a genotoxic murder mystery. Mol. Cell. 10:695-697.
38. Ramasamy R, Yan S F, Schmidt A M (2006). Methylglyoxal comes of AGE. Cell. 124:258-260.
39. Khan S A, Park S W, Huq M D, et al. (2006). Ligand-independent orphan receptor TR2 activation by phosphorylation at the DNA-binding domain. Proteomics. 6:123-130.
40. Sterner D E, Berger S L (2000). Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64:435-459.
41. Arrell D K, Neverova I, Van Eyk J E (2001). Cardiovascular proteomics: evolution and potential. Circ. Res. 88:763-773.
42. Scheler C, Muller E C, Stahl J, et al. (1997). Identification and characterization of heat shock protein 27 protein species in human myocardial two-dimensional electrophoresis patterns. Electrophoresis. 18:2823-2831.
43. Gong C X, Liu F, Grundke-Iqbal I, et al. (2005). Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Transmis. (Vienna, Austria), 112:813-838.
44. Yao D, Taguchi T, Matsumura T, et al. (2006). Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. Cell. 124:275-286.
45. Lapko V N, Smith D L, Smith J B (2001). In vivo carbamylation and acetylation of water-soluble human lens alphaB-crystallin lysine 92. Protein Sci. 10:1130-1136.
46. Mamula M J, Gee R J, Elliott J I, et al. (1999). Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J. Biol. Chem. 274:22321-22327.
47. Anni H, Israel Y (2002). Proteomics in alcohol research. Alcohol Res. Health. 26:219-232.
48. Anni H, Pristatsky P, Israel Y (2003). Binding of acetaldehyde to a glutathione metabolite: mass spectrometric characterization of an acetaldehyde-cysteinylglycine conjugate. Alcoholism, Clin. Exper. Res. 27:1613-1621.
49. Richon V M, O'Brien J P (2002). Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8:662-664.
50. Marks P A, Rifkind R A, Richon V M, et al. (2001). Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 1:194-202.
51. Kao H Y, Lee C H, Komarov A, et al. (2002). Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 277:187-193.
52. Landry J, Sutton A, Tafrov S T, et al. (2000). The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Nat. Acad. Sci. USA. 97:5807-5811.
53. Balasubramanyam K, Varier R A, Altaf M (2004). Curcumin, a novel p300/CREBbinding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279:51163-51171.
54. Cheng D, Yadav N, King R W, et al. (2004). Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem. 279:23892-23899.
55. Sebti S M (2005). Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 7:297-300.
56. Thomas X, Elhamri M (2005). Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia. Bulletin du Cancer. 92:227-238.
57. Garg A, Aggarwal B B (2002). Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 16:1053-1068.
58. Rohlff C (2000). Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis. 21:1227-1234.
59. Valaskovic G A, Kelleher N L (2002). Miniaturized formats for efficient mass spectrometry- based proteomics and therapeutic development. Curr. Topics Med. Chem. 2:1-12.